PACTR202205899389032已完成4 期
Effect of A Hemoglobinopathy Nursing Program on Pediatric Nursing Students' Performance: A Randomized Control Trial
Faculty of Nursing Benha University0 个研究点目标入组 108 人开始时间: 2022年5月6日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •pediatric nursing student at the third year, faculty of nursing, Benha University
排除标准
- •any student had a history of hemoglobinopathies
研究者
相似试验
已完成
不适用
Hemoglobinopathy Nursing Program and Pediatric Nursing StudentsHemoglobinopathiesNurse's RoleSickle Cell DiseaseThalassemiaNCT05389891Beni-Suef University108
招募中
不适用
The Impact of Hemoglobin Concentration during Hospital Course on Functional Outcome in Acute Ischemic Stroke PatientsDiseases of the nervous systemKCT0000248Seoul National University Bundang Hospital2,800
进行中（未招募）
1 期
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-GBbluebird bio, Inc.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-DEbluebird bio, Inc.94